ID   AMFR_HUMAN              Reviewed;         643 AA.
AC   Q9UKV5; P26442; Q8IZ70;
DT   19-SEP-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2003, sequence version 2.
DT   10-MAY-2017, entry version 150.
DE   RecName: Full=E3 ubiquitin-protein ligase AMFR;
DE            EC=2.3.2.27 {ECO:0000269|PubMed:11724934, ECO:0000269|PubMed:16168377};
DE   AltName: Full=Autocrine motility factor receptor;
DE            Short=AMF receptor;
DE   AltName: Full=RING finger protein 45;
DE   AltName: Full=RING-type E3 ubiquitin transferase AMFR {ECO:0000305};
DE   AltName: Full=gp78;
GN   Name=AMFR; Synonyms=RNF45;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|EMBL:AAD56722.1};
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX   PubMed=10456327; DOI=10.1016/S0014-5793(99)00966-7;
RA   Shimizu K., Tani M., Watanabe H., Nagamachi Y., Niinaka Y.,
RA   Shiroishi T., Ohwada S., Raz A., Yokota J.;
RT   "The autocrine motility factor receptor gene encodes a novel type of
RT   seven transmembrane protein.";
RL   FEBS Lett. 456:295-300(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 358-643.
RC   TISSUE=Placenta;
RX   PubMed=7626106; DOI=10.1006/bbrc.1995.2031;
RA   Huang B., Xie Y., Raz A.;
RT   "Identification of an upstream region that controls the transcription
RT   of the human autocrine motility factor receptor.";
RL   Biochem. Biophys. Res. Commun. 212:727-742(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 520-643.
RX   PubMed=1649192;
RA   Watanabe H., Carmi P., Hogan V., Raz T., Silletti S., Nabi I.R.,
RA   Raz A.;
RT   "Purification of human tumor cell autocrine motility factor and
RT   molecular cloning of its receptor.";
RL   J. Biol. Chem. 266:13442-13448(1991).
RN   [5]
RP   FUNCTION AS A UBIQUITIN LIGASE, CATALYTIC ACTIVITY, SUBCELLULAR
RP   LOCATION, AND INTERACTION WITH UBE2G2.
RX   PubMed=11724934; DOI=10.1073/pnas.251401598;
RA   Fang S., Ferrone M., Yang C., Jensen J.P., Tiwari S., Weissman A.M.;
RT   "The tumor autocrine motility factor receptor, gp78, is a ubiquitin
RT   protein ligase implicated in degradation from the endoplasmic
RT   reticulum.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:14422-14427(2001).
RN   [6]
RP   UBIQUITINATION OF APOB.
RX   PubMed=12670940; DOI=10.1074/jbc.M302683200;
RA   Liang J.S., Kim T., Fang S., Yamaguchi J., Weissman A.M., Fisher E.A.,
RA   Ginsberg H.N.;
RT   "Overexpression of the tumor autocrine motility factor receptor, gp78,
RT   a ubiquitin protein ligase (E3), results in increased ubiquitinylation
RT   and decreased secretion of apolipoprotein B100 in Hep G2 cells.";
RL   J. Biol. Chem. 278:23984-23988(2003).
RN   [7]
RP   INTERACTION WITH INSIG1 AND VCP, FUNCTION, CATALYTIC ACTIVITY, AND
RP   MUTAGENESIS OF CYS-356.
RX   PubMed=16168377; DOI=10.1016/j.molcel.2005.08.009;
RA   Song B.L., Sever N., DeBose-Boyd R.A.;
RT   "Gp78, a membrane-anchored ubiquitin ligase, associates with Insig-1
RT   and couples sterol-regulated ubiquitination to degradation of HMG CoA
RT   reductase.";
RL   Mol. Cell 19:829-840(2005).
RN   [8]
RP   INTERACTION WITH DERL1 AND VCP.
RX   PubMed=16186510; DOI=10.1073/pnas.0505006102;
RA   Ye Y., Shibata Y., Kikkert M., van Voorden S., Wiertz E.,
RA   Rapoport T.A.;
RT   "Recruitment of the p97 ATPase and ubiquitin ligases to the site of
RT   retrotranslocation at the endoplasmic reticulum membrane.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:14132-14138(2005).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-516, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   FUNCTION.
RX   PubMed=19103148; DOI=10.1016/j.abb.2008.12.001;
RA   Pabarcus M.K., Hoe N., Sadeghi S., Patterson C., Wiertz E.,
RA   Correia M.A.;
RT   "CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor
RT   receptor, AMFR) and CHIP E3 ligases.";
RL   Arch. Biochem. Biophys. 483:66-74(2009).
RN   [11]
RP   INTERACTION WITH BAG6.
RX   PubMed=21636303; DOI=10.1016/j.molcel.2011.05.010;
RA   Wang Q., Liu Y., Soetandyo N., Baek K., Hegde R., Ye Y.;
RT   "A ubiquitin ligase-associated chaperone holdase maintains
RT   polypeptides in soluble states for proteasome degradation.";
RL   Mol. Cell 42:758-770(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-542, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH USP13.
RX   PubMed=24424410; DOI=10.7554/eLife.01369;
RA   Liu Y., Soetandyo N., Lee J.G., Liu L., Xu Y., Clemons W.M. Jr.,
RA   Ye Y.;
RT   "USP13 antagonizes gp78 to maintain functionality of a chaperone in
RT   ER-associated degradation.";
RL   Elife 3:E01369-E01369(2014).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-523, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [15]
RP   STRUCTURE BY NMR OF 452-502.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of RSGI RUH-076, a human CUE domain.";
RL   Submitted (SEP-2007) to the PDB data bank.
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 622-640 IN COMPLEX WITH VCP,
RP   AND VIM MOTIF.
RX   PubMed=21914798; DOI=10.1074/jbc.M111.274506;
RA   Hanzelmann P., Schindelin H.;
RT   "The structural and functional basis of the p97/valosin-containing
RT   protein (VCP)-interacting motif (VIM): mutually exclusive binding of
RT   cofactors to the N-terminal domain of p97.";
RL   J. Biol. Chem. 286:38679-38690(2011).
RN   [17]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-605.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that mediates the
CC       polyubiquitination of a number of proteins such as CD3D, CYP3A4,
CC       CFTR and APOB for proteasomal degradation. Component of a VCP/p97-
CC       AMFR/gp78 complex that participates in the final step of
CC       endoplasmic reticulum-associated degradation (ERAD). The VCP/p97-
CC       AMFR/gp78 complex is involved in the sterol-accelerated ERAD
CC       degradation of HMGCR through binding to the HMGCR-INSIG complex at
CC       the ER membrane and initiating ubiquitination of HMGCR. The
CC       ubiquitinated HMGCR is then released from the ER by the complex
CC       into the cytosol for subsequent destruction. Also regulates ERAD
CC       through the ubiquitination of UBL4A a component of the BAG6/BAT3
CC       complex. Also acts as a scaffold protein to assemble a complex
CC       that couples ubiquitination, retranslocation and deglycosylation.
CC       Mediates tumor invasion and metastasis as a receptor for the
CC       GPI/autocrine motility factor. {ECO:0000269|PubMed:10456327,
CC       ECO:0000269|PubMed:11724934, ECO:0000269|PubMed:16168377,
CC       ECO:0000269|PubMed:19103148, ECO:0000269|PubMed:24424410}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine. {ECO:0000269|PubMed:11724934,
CC       ECO:0000269|PubMed:16168377}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with RNF5. Also forms an ERAD complex
CC       containing VCP/p97, NGLY1; PSMC1; SAKS1 AND RAD23B required for
CC       coupling retrotranslocation, ubiquitination and deglycosylation
CC       (By similarity). Interacts with DRL1. Interacts (through a region
CC       distinct from the RING finger) with UBE2G2/UBC7. Component of the
CC       VCP/p97-AMFR/gp78 complex that enhances VCP/p97 binding to
CC       polyubiquitinated proteins for their degradation by the
CC       endoplasmic reticulum-associated degradation (ERAD) pathway.
CC       Interacts (via the VIM) with VCP/p97. Interacts (via its membrane
CC       domain) with INSIG1; the interaction initiates the sterol-mediated
CC       ubiquitination and degradation of HMGCR by the ERAD pathway.
CC       Interacts with BAG6 (PubMed:21636303). Interacts with USP13 (via
CC       UBA 2 domain); the interaction is direct (PubMed:24424410).
CC       {ECO:0000250, ECO:0000269|PubMed:11724934,
CC       ECO:0000269|PubMed:16168377, ECO:0000269|PubMed:16186510,
CC       ECO:0000269|PubMed:21636303, ECO:0000269|PubMed:21914798,
CC       ECO:0000269|PubMed:24424410}.
CC   -!- INTERACTION:
CC       O94905:ERLIN2; NbExp=8; IntAct=EBI-1046367, EBI-4400770;
CC       O15503:INSIG1; NbExp=2; IntAct=EBI-1046367, EBI-6252425;
CC       P60604:UBE2G2; NbExp=18; IntAct=EBI-1046367, EBI-1051028;
CC       P55072:VCP; NbExp=8; IntAct=EBI-1046367, EBI-355164;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:11724934}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:11724934}.
CC   -!- DOMAIN: The VCP/p97-interacting motif (VIM) is sufficient for
CC       binding VCP/p97 to form a complex capable of transferring VCP/p97
CC       from the cytosol to microsomes.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA36671.1; Type=Miscellaneous discrepancy; Note=Several sequencing errors.; Evidence={ECO:0000305};
CC       Sequence=AAA79362.1; Type=Frameshift; Positions=355, 388, 411, 487, 537, 583, 632; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AMFRID627ch16q12.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF124145; AAD56722.1; -; mRNA.
DR   EMBL; BC069197; AAH69197.1; -; mRNA.
DR   EMBL; L35233; AAA79362.1; ALT_FRAME; mRNA.
DR   EMBL; M63175; AAA36671.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS10758.1; -.
DR   PIR; A39877; A39877.
DR   RefSeq; NP_001135.3; NM_001144.5.
DR   RefSeq; NP_001310441.1; NM_001323512.1.
DR   UniGene; Hs.295137; -.
DR   PDB; 2EJS; NMR; -; A=452-502.
DR   PDB; 2LVN; NMR; -; C=453-504.
DR   PDB; 2LVO; NMR; -; C=453-504.
DR   PDB; 2LVP; NMR; -; C=453-504.
DR   PDB; 2LVQ; NMR; -; D=453-504.
DR   PDB; 2LXH; NMR; -; C=313-393.
DR   PDB; 2LXP; NMR; -; B=574-600, C=327-384.
DR   PDB; 3FSH; X-ray; 2.76 A; C=574-601.
DR   PDB; 3H8K; X-ray; 1.80 A; B=573-600.
DR   PDB; 3TIW; X-ray; 1.80 A; C/D=622-640.
DR   PDB; 4G3O; X-ray; 1.60 A; A=456-498.
DR   PDB; 4LAD; X-ray; 2.30 A; B=313-393, B=574-600.
DR   PDBsum; 2EJS; -.
DR   PDBsum; 2LVN; -.
DR   PDBsum; 2LVO; -.
DR   PDBsum; 2LVP; -.
DR   PDBsum; 2LVQ; -.
DR   PDBsum; 2LXH; -.
DR   PDBsum; 2LXP; -.
DR   PDBsum; 3FSH; -.
DR   PDBsum; 3H8K; -.
DR   PDBsum; 3TIW; -.
DR   PDBsum; 4G3O; -.
DR   PDBsum; 4LAD; -.
DR   ProteinModelPortal; Q9UKV5; -.
DR   SMR; Q9UKV5; -.
DR   BioGrid; 106764; 121.
DR   DIP; DIP-29060N; -.
DR   IntAct; Q9UKV5; 25.
DR   MINT; MINT-2821880; -.
DR   STRING; 9606.ENSP00000290649; -.
DR   iPTMnet; Q9UKV5; -.
DR   PhosphoSitePlus; Q9UKV5; -.
DR   BioMuta; AMFR; -.
DR   DMDM; 34922250; -.
DR   EPD; Q9UKV5; -.
DR   MaxQB; Q9UKV5; -.
DR   PaxDb; Q9UKV5; -.
DR   PeptideAtlas; Q9UKV5; -.
DR   PRIDE; Q9UKV5; -.
DR   Ensembl; ENST00000290649; ENSP00000290649; ENSG00000159461.
DR   GeneID; 267; -.
DR   KEGG; hsa:267; -.
DR   UCSC; uc002eiy.4; human.
DR   CTD; 267; -.
DR   DisGeNET; 267; -.
DR   GeneCards; AMFR; -.
DR   HGNC; HGNC:463; AMFR.
DR   HPA; CAB026381; -.
DR   HPA; HPA029018; -.
DR   HPA; HPA077835; -.
DR   MIM; 603243; gene.
DR   neXtProt; NX_Q9UKV5; -.
DR   OpenTargets; ENSG00000159461; -.
DR   PharmGKB; PA24768; -.
DR   eggNOG; KOG0802; Eukaryota.
DR   eggNOG; COG5243; LUCA.
DR   GeneTree; ENSGT00530000062938; -.
DR   HOGENOM; HOG000172151; -.
DR   HOVERGEN; HBG044694; -.
DR   InParanoid; Q9UKV5; -.
DR   KO; K10636; -.
DR   OMA; GTWESKG; -.
DR   OrthoDB; EOG091G06NX; -.
DR   PhylomeDB; Q9UKV5; -.
DR   TreeFam; TF320052; -.
DR   BRENDA; 2.3.2.B10; 2681.
DR   Reactome; R-HSA-532668; N-glycan trimming in the ER and Calnexin/Calreticulin cycle.
DR   Reactome; R-HSA-901032; ER Quality Control Compartment (ERQC).
DR   SIGNOR; Q9UKV5; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; AMFR; human.
DR   EvolutionaryTrace; Q9UKV5; -.
DR   GeneWiki; AMFR; -.
DR   GenomeRNAi; 267; -.
DR   PRO; PR:Q9UKV5; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000159461; -.
DR   CleanEx; HS_AMFR; -.
DR   ExpressionAtlas; Q9UKV5; baseline and differential.
DR   Genevisible; Q9UKV5; HS.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0036513; C:Derlin-1 retrotranslocation complex; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0044322; C:endoplasmic reticulum quality control compartment; IEA:GOC.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0030426; C:growth cone; IEA:Ensembl.
DR   GO; GO:0030176; C:integral component of endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0043234; C:protein complex; IDA:MGI.
DR   GO; GO:1904288; F:BAT3 complex binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0051087; F:chaperone binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0030674; F:protein binding, bridging; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0004872; F:receptor activity; IPI:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1904264; F:ubiquitin protein ligase activity involved in ERAD pathway; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:1990381; F:ubiquitin-specific protease binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0034450; F:ubiquitin-ubiquitin ligase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:1904380; P:endoplasmic reticulum mannose trimming; TAS:Reactome.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; IMP:UniProtKB.
DR   GO; GO:0036503; P:ERAD pathway; IC:ParkinsonsUK-UCL.
DR   GO; GO:0007611; P:learning or memory; IEA:Ensembl.
DR   GO; GO:0006928; P:movement of cell or subcellular component; TAS:ProtInc.
DR   GO; GO:0032092; P:positive regulation of protein binding; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0051865; P:protein autoubiquitination; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006457; P:protein folding; TAS:Reactome.
DR   GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0051259; P:protein oligomerization; IDA:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0030433; P:ubiquitin-dependent ERAD pathway; IDA:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR003892; CUE.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   Pfam; PF02845; CUE; 1.
DR   Pfam; PF13639; zf-RING_2; 1.
DR   SMART; SM00546; CUE; 1.
DR   SMART; SM00184; RING; 1.
DR   PROSITE; PS51140; CUE; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Endoplasmic reticulum; Membrane;
KW   Metal-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Transferase; Transmembrane; Transmembrane helix;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    643       E3 ubiquitin-protein ligase AMFR.
FT                                /FTId=PRO_0000064579.
FT   TRANSMEM     82    102       Helical. {ECO:0000255}.
FT   TRANSMEM    122    142       Helical. {ECO:0000255}.
FT   TRANSMEM    145    165       Helical. {ECO:0000255}.
FT   TRANSMEM    186    206       Helical. {ECO:0000255}.
FT   TRANSMEM    215    235       Helical. {ECO:0000255}.
FT   TRANSMEM    276    296       Helical. {ECO:0000255}.
FT   TRANSMEM    429    449       Helical. {ECO:0000255}.
FT   DOMAIN      456    498       CUE. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00468}.
FT   ZN_FING     341    379       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   REGION      622    640       VCP/p97-interacting motif (VIM).
FT                                {ECO:0000269|PubMed:21914798}.
FT   MOD_RES     516    516       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     523    523       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     542    542       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VARIANT     605    605       D -> V (in a breast cancer sample;
FT                                somatic mutation; dbSNP:rs373191257).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035790.
FT   MUTAGEN     356    356       C->G: No degradation of HMGCR.
FT                                {ECO:0000269|PubMed:16168377}.
FT   CONFLICT    406    406       V -> D (in Ref. 3; AAA79362).
FT                                {ECO:0000305}.
FT   CONFLICT    491    491       D -> V (in Ref. 3; AAA79362).
FT                                {ECO:0000305}.
FT   CONFLICT    500    500       V -> L (in Ref. 3; AAA79362).
FT                                {ECO:0000305}.
FT   CONFLICT    614    614       S -> L (in Ref. 1; AAD56722).
FT                                {ECO:0000305}.
FT   HELIX       332    337       {ECO:0000244|PDB:2LXH}.
FT   STRAND      342    344       {ECO:0000244|PDB:4LAD}.
FT   STRAND      351    353       {ECO:0000244|PDB:4LAD}.
FT   STRAND      355    357       {ECO:0000244|PDB:2LXH}.
FT   STRAND      359    361       {ECO:0000244|PDB:4LAD}.
FT   HELIX       362    369       {ECO:0000244|PDB:4LAD}.
FT   STRAND      376    378       {ECO:0000244|PDB:4LAD}.
FT   HELIX       456    467       {ECO:0000244|PDB:4G3O}.
FT   HELIX       473    483       {ECO:0000244|PDB:4G3O}.
FT   HELIX       486    494       {ECO:0000244|PDB:4G3O}.
FT   HELIX       575    599       {ECO:0000244|PDB:3H8K}.
FT   HELIX       625    637       {ECO:0000244|PDB:3TIW}.
SQ   SEQUENCE   643 AA;  72996 MW;  8782324609C0E62A CRC64;
     MPLLFLERFP WPSLRTYTGL SGLALLGTII SAYRALSQPE AGPGEPDQLT ASLQPEPPAP
     ARPSAGGPRA RDVAQYLLSD SLFVWVLVNT ACCVLMLVAK LIQCIVFGPL RVSERQHLKD
     KFWNFIFYKF IFIFGVLNVQ TVEEVVMWCL WFAGLVFLHL MVQLCKDRFE YLSFSPTTPM
     SSHGRVLSLL VAMLLSCCGL AAVCSITGYT HGMHTLAFMA AESLLVTVRT AHVILRYVIH
     LWDLNHEGTW EGKGTYVYYT DFVMELTLLS LDLMHHIHML LFGNIWLSMA SLVIFMQLRY
     LFHEVQRRIR RHKNYLRVVG NMEARFAVAT PEELAVNNDD CAICWDSMQA ARKLPCGHLF
     HNSCLRSWLE QDTSCPTCRM SLNIADNNRV REEHQGENLD ENLVPVAAAE GRPRLNQHNH
     FFHFDGSRIA SWLPSFSVEV MHTTNILGIT QASNSQLNAM AHQIQEMFPQ VPYHLVLQDL
     QLTRSVEITT DNILEGRIQV PFPTQRSDSI RPALNSPVER PSSDQEEGET SAQTERVPLD
     LSPRLEETLD FGEVEVEPSE VEDFEARGSR FSKSADERQR MLVQRKDELL QQARKRFLNK
     SSEDDAASES FLPSEGASSD PVTLRRRMLA AAAERRLQKQ QTS
//
